Non-PAZ RCC Chart Study in US, EU and Asia-Pacific

Trial description: The goal of this retrospective medical records chart review study is to assess the real-world treatment patterns, safety, efficacy, and costs of anti-angiogenesis agents in patients with advanced renal cell carcinoma (RCC) over the course of angiogenesis inhibitor treatment. No treatment interventions are given as part of this study. Medical records of patients with RCC who received sorafenib, sunitinib, temsirolimus, or bevacizumab will be reviewed and relevant information abstracted. Data abstracted include prescriptions/administration of angiogenesis inhibitors and other anti-cancer agents, tumor response, diagnoses/identification of key adverse events (e.g., diarrhea, fatigue, hypertension, hypothyroidism, hand-foot syndrome), medical resource utilization, and socio-demographic factors (e.g., race, age, gender, insurance type). Chart reviews will be conducted in the US, Italy, France, Spain, Ireland, UK, Taiwan, Korea and Denmark. The observation period for each patient extends from initiation of a patient’s first angiogenesis inhibitor to the earliest of death, loss to follow-up, or end of the study period. Treatment patterns endpoints include rates of dose changes and interruptions, rates of discontinuations, and switching among agents, and reasons for these treatment modifications. Efficacy endpoints include ORR, PFS and OS. Safety endpoints include the proportion of patients experiencing key adverse events. Costs are modeled based on medical resource utilization.